TrialJournal for immunotherapy of cancer2026

Phase 2 trial of pTVG-HP ± pTVG-AR DNA vaccines and pembrolizumab in patients with metastatic, castration-resistant prostate cancer (mCRPC).

Christos E Kyriakopoulos et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.